In recent years, most of the interest in the medicinal cannabis market has been focused on CBD (THC-free) and, to a lesser extent, THC. However, the market needs are changing with increasing interest now seen in the so-called minor cannabinoids. In this post, I will focus on cannabinol (CBN).
It (almost) doesn’t matter what the intended therapeutic outcome is, for virtually everyone who is working in the business of cannabis processing, CBD / THC remediation proceeds through well recognised processing steps. The introduction of newer legislation has come the (justified) need to ensure the industry runs in a smooth and orderly manner in order to keep outputting products of defined quality. It doesn't matter where on the globe you are, processes are becoming enshrined in and outputs more and more needing to comply with strict standards from quality and legislative directives. % Limits of THC content for example is one of the biggest considerations in many countries right now and already set in many legislative goals.
Welcome to a second installment of the Biotage Cannabis Application development flash blog. The first post, dated August 20 2016, outlined an orthogonal approach to isolating cannabinoids from winterized extract. Give it read if you have not seen it
Today we investigate the “hot” topic of pesticide elimination from extract. Specifically – Myclobutanil remediation.
Cannabis entrepreneurs continually seek to differentiate themselves from others in the market. Some focus on THC while others focus on CBD. What I have seen recently after attending some cannabis-specific conferences is a growing interest in isolating/purifying some of the minor, naturally occurring phytocannabinoids such as CBG and CBDV.